FENTANYL TRANSDERMAL 25 ug/h

Fentanyl, the active ingredient in FENTANYL TRANSDERMAL, is an opioid analgesic presented as a 25 µg/hour transdermal patch for transdermal use. It is used to manage chronic severe cancer pain and severe chronic non-cancer pain in patients who are opioid-tolerant.

GNH USA supplies FENTANYL TRANSDERMAL as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

FENTANYL TRANSDERMAL is an opioid analgesic used to manage severe pain.

- Chronic severe cancer pain: Used for managing persistent, severe pain in cancer patients who are opioid-tolerant. - Severe chronic non-cancer pain: Used for managing severe chronic pain in patients who are opioid-tolerant and for whom alternative treatment options are inadequate.

FENTANYL TRANSDERMAL may cause various side effects, ranging from common to serious.

Common Side Effects: - Nausea - Vomiting - Constipation - Dizziness - Drowsiness - Headache - Dry mouth - Itching

Serious or Rare Side Effects: - Respiratory depression - Hypotension - Seizures - Allergic reactions - Skin discoloration or rash at the application site - Swelling or itching at the application site

FENTANYL TRANSDERMAL should be used with caution and under medical supervision.

- Administration: Only prescribed by doctors experienced in treating severe pain. - Tolerance: Should only be used by patients who are tolerant to opioid medications. - Respiratory Depression: Monitor closely for signs of respiratory depression. - Children and Pets: Keep out of reach of children and pets to prevent accidental exposure. - Disposal: Dispose of used patches according to manufacturer's instructions. - Store below 25°C: Keep in the original packaging, protect from moisture and light.

FENTANYL TRANSDERMAL may interact with other medications, potentially affecting its efficacy or increasing the risk of side effects.

Major Interactions (Avoid): - Other opioids: Increased risk of respiratory depression and sedation. - Benzodiazepines: Increased risk of respiratory depression and sedation. - MAO inhibitors: Increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antidepressants: Increased risk of serotonin syndrome. - Antipsychotics: Increased risk of respiratory depression and sedation. - Alcohol: Increased risk of respiratory depression and sedation.